USC-led team of scientists recreates DNA-mending pathway in test-tube

December 02, 2004

Los Angeles, Dec. 2, 2004- One of five known DNA-repair mechanisms in cells has been completely analyzed and reconstituted in a test tube by an international collaboration of researchers led by scientists from the Keck School of Medicine of the University of Southern California. The team is the first ever to reconstitute this pathway, known as the nonhomologous end joining pathway, or NHEJ, and NHEJ is only the third repair pathway to be reconstituted in the laboratory.

The findings were published in the December 3, 2004 issue of Molecular Cell.

Understanding how DNA repair works is critical to understanding the development of cancer, which often occurs when DNA is not properly repaired.

In addition, notes Michael Lieber, M.D., Ph.D., the Rita and Edward Polusky Chair in Basic Cancer Research at the Keck School who heads up the molecular genetics program at the USC/Norris Comprehensive Cancer Center and was principal investigator on this study, the ability to reconstitute the pathway has important practical implications.

"Now we can really test for drugs that will affect the pathway," he said. "For instance, one of the things this pathway is particularly good at is repairing radiation damage. When people get radiation treatment, both the normal and the tumor cells will use this pathway to resist the radiation. If we could inhibit the pathway regionally in or around the tumor, we could really make radiation dramatically more effective."

In order for the team to reconstitute the NHEJ pathway, which is found in all cells that are evolutionarily 'above' yeast, they first had to purify all the proteins used to rejoin the double strands of DNA once they've suffered damage and are severed from one another. As it turned out, two of the seven proteins come from a class of polymerases that were discovered in 1999 by Myron Goodman, Ph.D., professor of molecular biology at the USC College of Letters, Arts and Sciences, who became an essential part of this research team.

"Before this, no one knew what this class was good for," Lieber explains. "This is really the first solid indication of what two of these polymerases might do."

Knowledge of the details of the NHEJ pathway extends beyond its connections to cancer and radiation treatment, Lieber notes.

"This pathway gets used not just for accidental damage, oxidative damage and radiation damage to DNA, but is also used in the immune system," he explains. "So the immune system would function less well without it."
-end-
The work featured in Molecular Cell was supported by the National Institutes of Health.

Yunmei Ma, Haihui Lu, Brigette Tippin, Myron F. Goodman, Noriko Shimazaki, Osamu Koiwai, Chih-Lin Hsieh, Klaus Schwarz, Michael R. Lieber, "A Biochemically Defined System for Mammalian Nonhomologous DNA End Joining." Molecular Cell, Volume 16, Number 5, December 3, 2004.

University of Southern California

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.